Abstract

A REVIEW ON THE USE OF FAVIPIRAVIR IN TREATMENT OF COVID 19

Amitha Mary Samson*, Pranith P. L., E. Samjeeva Kumar and Prasobh G. R.

.

Abstract

COVID 19 was originated from the province of Hubei in China in 2019 and now it has already spread all around the globe and has cause great socioeconomic impact. It’s is an infectious disease associated with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). In early phase of infection there might be only mild symptoms and then the symptoms progresses in elderly population and persons with comorbidity are at high risk of infection. Commonly the symptoms appears within 2 to 14 days of exposure. The main symptoms include fever, cough, tiredness, sore throat, diarrhea and in serious condition it can lead to breathing difficult, chest pain, loss of speech and movement. Repurposed drugs are being evaluated to hasten the treatment process. Use of several drugs are being evaluated for the treatment of COVID 19. Favipirarvir is one such drug, the oral form of the drug have been approved for the new and re-emerging pandemic influenza in Japan in 2014. It has shown potent in vitro activity against SARS CoV -2. Favipiravir showed better therapeutic response on COVID-19 in both disease progression and viral clearance. The main intention of this study is to produce a comprehensive review of the role, safety, efficacy of favipiravir in treatment of COVID 19.

Keywords: Favipiravir, SARS - CoV-2, anti viral, Pneumonia.